Collegium Pharmaceutical Inc (COLL)
35.48
-0.46
(-1.29%)
USD |
NASDAQ |
Apr 24, 16:00
35.48
0.00 (0.00%)
After-Hours: 16:52
Collegium Pharmaceutical Enterprise Value: 1.505B for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 1.505B |
| April 22, 2024 | 1.467B |
| April 19, 2024 | 1.470B |
| April 18, 2024 | 1.468B |
| April 17, 2024 | 1.490B |
| April 16, 2024 | 1.488B |
| April 15, 2024 | 1.480B |
| April 12, 2024 | 1.498B |
| April 11, 2024 | 1.520B |
| April 10, 2024 | 1.571B |
| April 09, 2024 | 1.596B |
| April 08, 2024 | 1.616B |
| April 05, 2024 | 1.635B |
| April 04, 2024 | 1.613B |
| April 03, 2024 | 1.617B |
| April 02, 2024 | 1.584B |
| April 01, 2024 | 1.599B |
| March 28, 2024 | 1.597B |
| March 27, 2024 | 1.664B |
| March 26, 2024 | 1.633B |
| March 25, 2024 | 1.640B |
| March 22, 2024 | 1.626B |
| March 21, 2024 | 1.624B |
| March 20, 2024 | 1.596B |
| March 19, 2024 | 1.570B |
| Date | Value |
|---|---|
| March 18, 2024 | 1.614B |
| March 15, 2024 | 1.606B |
| March 14, 2024 | 1.572B |
| March 13, 2024 | 1.581B |
| March 12, 2024 | 1.552B |
| March 11, 2024 | 1.555B |
| March 08, 2024 | 1.558B |
| March 07, 2024 | 1.546B |
| March 06, 2024 | 1.529B |
| March 05, 2024 | 1.517B |
| March 04, 2024 | 1.540B |
| March 01, 2024 | 1.543B |
| February 29, 2024 | 1.530B |
| February 28, 2024 | 1.525B |
| February 27, 2024 | 1.532B |
| February 26, 2024 | 1.525B |
| February 23, 2024 | 1.518B |
| February 22, 2024 | 1.405B |
| February 21, 2024 | 1.372B |
| February 20, 2024 | 1.382B |
| February 16, 2024 | 1.398B |
| February 15, 2024 | 1.442B |
| February 14, 2024 | 1.407B |
| February 13, 2024 | 1.385B |
| February 12, 2024 | 1.434B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
202.30M
Minimum
Jul 22 2019
1.664B
Maximum
Mar 27 2024
933.17M
Average
905.41M
Median
Jul 13 2021
Enterprise Value Benchmarks
| Immunogen Inc (DELISTED) | -- |
| Supernus Pharmaceuticals Inc | 1.386B |
| AnaptysBio Inc | 122.41M |
| Recursion Pharmaceuticals Inc | 1.416B |
| Nuvalent Inc | 3.611B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 31.94M |
| Revenue (Quarterly) | 149.74M |
| Total Expenses (Quarterly) | 88.06M |
| EPS Diluted (Quarterly) | 0.83 |
| Gross Profit Margin (Quarterly) | 63.19% |
| Profit Margin (Quarterly) | 21.33% |
| Earnings Yield | 3.35% |
| Operating Earnings Yield | 10.40% |
| Normalized Earnings Yield | 5.272 |